Nanoparticles for Cancer Therapy: Current Progress and Challenges
By Shreelaxmi Gavas, Sameer Quazi, Tomasz M. Karpinski. Nanoscale Research Letters, 2021
805 citations recorded by the source corpus.
Cancer is one of the leading causes of death and morbidity with a complex pathophysiology. Traditional cancer therapies include chemotherapy, radiation therapy, targeted therapy, and immunotherapy. However, limitations such as lack of specificity, cytotoxicity, and multi-drug resistance pose a substantial challenge for favorable cancer treatment. The advent of nanotechnology has revolutionized the arena of cancer diagnosis and treatment. Nanoparticles (1–100 nm) can be used to treat cancer due to their specific advantages such as biocompatibility, reduced toxicity, more excellent stability, enhanced permeability and retention effect, and precise targeting. Nanoparticles are classified into several main categories. The nanoparticle drug delivery system is particular and utilizes tumor and tumor environment characteristics. Nanoparticles not only solve the limitations of conventional cancer treatment but also overcome multidrug resistance. Additionally, as new multidrug resistance mechanisms are unraveled and studied, nanoparticles are being investigated more vigorously. Various therapeutic implications of nanoformulations have created brand new perspectives for cancer treatment. However, most of the research is limited to in vivo and in vitro studies, and the number of approved nanodrugs has not much amplified over the years. This review discusses numerous types of nanoparticles, targeting mechanisms, and approved nanotherapeutics for oncological implications in cancer treatment. Further, we also summarize the current perspective, advantages, and challenges in clinical translation.
Subfields: Biomaterials, Biomedical Engineering, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/3ffee193f344bf3afd713e11e5e528a0deb77b60
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomaterials
In Biomedical Engineering
In Molecular Biology
Citations in the corpus
- Artificial intelligence and machine learning in precision and genomic medicine (2021, background): “The advent of targeted treatment has made growth in precision medicine [209].”